Journal of Radiology
Open Access

Cancer remains a significant global health challenge, affecting millions of lives every year. Advances in chemotherapy have greatly improved cancer treatment, but it is not without side effects. One particular chemotherapy agent, 5-Fluorouracil (5-FU), is commonly used to treat various types of cancers, including colorectal, breast, and gastrointestinal malignancies [1]. However, recent studies have raised concerns about its potential impact on the cardiovascular system, particularly on the electrocardiogram (ECG) of patients undergoing treatment. In this article, we will delve into the changes in the electrocardiogram observed in cancer patients receiving 5-FU chemotherapy and the implications for clinical management.

The cardiovascular effects of 5-Fluorouracil chemotherapy

5-FU is an antimetabolite drug that interferes with the synthesis of DNA and RNA, leading to the inhibition of cell proliferation. While its main target is rapidly dividing cancer cells, it can also affect healthy cells, including those in the cardiovascular system. As a result, 5-FU chemotherapy has been associated with various cardiovascular side effects, ranging from mild symptoms to potentially life-threatening complications [2].

Changes in Electrocardiogram (ECG) patterns

One of the crucial diagnostic tools for assessing cardiac function is the electrocardiogram (ECG or EKG). An ECG records the electrical activity of the heart and can provide valuable insights into heart rhythm and structure. In cancer patients receiving 5-FU chemotherapy, several changes in ECG patterns have been observed, including:

QT interval prolongation: The QT interval represents the time from the start of the Q wave to the end of the T wave on the ECG. Prolongation of the QT interval is a concerning finding as it may increase the risk of developing life-threatening ventricular arrhythmias, such as Torsades de Pointes.

ST-T segment changes: ST-segment depression or elevation may occur during 5-FU chemotherapy, indicating myocardial ischemia or injury [3]. These changes can be reversible or, in severe cases, lead to myocardial infarction.

Arrhythmias: Patients undergoing 5-FU treatment may experience various arrhythmias, including bradyarrhythmias (slow heart rhythms) and tachyarrhythmias (fast heart rhythms). These arrhythmias can be symptomatic or occur without apparent symptoms.

Sinus node dysfunction: The sinus node, responsible for initiating the heart’s electrical impulses, can be affected by 5-FU, leading to sinus bradycardia or sinus arrest.

Atrial fibrillation: 5-FU has been associated with an increased risk of developing atrial fibrillation, a common arrhythmia characterized by irregular and often rapid heartbeats.

Mechanisms underlying ECG changes

The exact mechanisms by which 5-FU induces ECG changes are not fully understood. However, several hypotheses have been proposed:

Direct toxicity: 5-FU and its metabolites may exert direct toxic effects on cardiac ion channels, leading to altered electrical conductance and subsequently affecting the ECG.

Coronary vasospasm: 5-FU can cause endothelial dysfunction and coronary vasospasm, reducing blood flow to the heart muscle and resulting in ischemia and ECG changes.

Neurotoxic effects: 5-FU may interfere with the autonomic nervous system, influencing heart rate and rhythm.

Clinical implications and management

The detection of ECG changes in cancer patients undergoing 5-FU chemotherapy is crucial for timely intervention and improved patient outcomes. Oncologists and cardiologists should collaborate to monitor patients closely during treatment. Some essential considerations include:

Baseline ECG: A baseline ECG before starting chemotherapy can serve as a reference for identifying any subsequent changes.

Regular ECG monitoring: Regular ECG monitoring during chemotherapy sessions and in the days following treatment can help detect early signs of cardiac toxicity.

Electrolyte monitoring: 5-FU treatment can lead to electrolyte imbalances, which can further exacerbate cardiac complications. Close monitoring and appropriate correction of electrolyte levels are vital.

Risk assessment: Patients with pre-existing cardiovascular conditions may be at a higher risk of developing severe cardiac side effects. Individualized risk assessment is necessary for optimal patient care [4].

Cardio protective measures: In some cases, cardio protective medications such as beta-blockers may be considered to mitigate the cardiovascular effects of 5-FU [5].

Conclusion

5-Fluorouracil chemotherapy has been a mainstay in cancer treatment, saving countless lives. However, it is essential to recognize its potential impact on the cardiovascular system, particularly in terms of ECG changes. Regular monitoring, prompt identification of abnormalities, and early intervention are vital to minimize cardiac complications and ensure the best possible outcomes for cancer patients undergoing 5-FU treatment. Collaboration between oncologists and cardiologists is essential to strike the right balance between effective cancer treatment and preserving cardiac health. Further research is needed to better understand the mechanisms underlying ECG changes in these patients and to develop more targeted and safer treatment strategies.

Acknowledgement

None

Conflict of Interest

None

1. Ensley JF, Patel B, Kloner R, Kish JA, Wynne J, et al. (1989) The clinical syndrome of 5-fluorouracil cardiotoxicity. Invest New Drugs7: 101-109.

Indexed at, Google Scholar, Crossref

2. Millward MJ, Ganju V, Buck M (1988) Cardiac arrest- -a manifestation of 5-fluorouracil cardiotoxicity. Aust N Z J Med 18: 693-695.

Indexed at, Google Scholar, Crossref

3. Wang X, Yang Y, Dong J, Wang X, Zheng Y, et al. (2021) A comparative study on the tip position of peripherally inserted central catheter inserted at two forward P-wave amplitudes by intracavitary electrocardiogram in cancer patients. Ann Palliat Med 10: 10228-10235.

Indexed at, Google Scholar, Crossref

4. Zou S, Zhang Q, Gao S, Luo M, Gan X, et al.(2022) Electrocardiogram manifestations of hyponatraemia. Cardiovasc J Afr 33: 98-100.

Indexed at, Google Scholar, Crossref

5. Guo Y, Koshy S, Hui D, Palmer JL, Shin K, et al. (2015) Prognostic Value of Heart Rate Variability in Patients With Cancer. J Clin Neurophysiol. 32: 516-520.

Indexed at, Google Scholar, Crossref